One Wales Medicines interim decisions

Azacitidine for progressive angioimmunoblastic T-cell lymphoma (OW16): Last review date: September 2023

Arsenic trioxide for high risk acute promyelocytic leukaemia (OW06): Last review date: September 2023

Rituximab for pemphigus and pemphigoid (OW10): Last review date: July 2023

Dostarlimab (Jemperli®) for locally advanced rectal cancer (OW26): Issue date: 03/08/2023

Rituximab for myasthenia gravis (OW12) - reassessment: Issue date: 26/04/2023

Ustekinumab (Stelara®) for the treatment of inflammatory bowel disease in children (OW25): Issue date: 02/03/2023

Vedolizumab (Entyvio®) for the treatment of inflammatory bowel disease in children (OW24): Issue date: 02/03/2023

Infliximab for the treatment of refractory pulmonary sarcoidosis (OW23): Issue date: 02/03/2023

Denosumab (Prolia®) for osteoporosis in men (OW07): Last review date: 11/12/2022

Vedolizumab (Entyvio®) for the treatment of ICI induced enterocolitis (OW22): Issue date: 02/02/2023

Infliximab for the treatment of ICI induced enterocolitis (OW21): Issue date: 02/02/2023

Bendamustine and rituximab for mantle cell lymphoma (OW09): Last review date: 06/12/2022

Bendamustine and rituximab for indolent lymphomas (OW08): Last review date: 06/12/2022

Bevacizumab for ovarian cancer (OW01): Last review date: 06/12/2022

Abiraterone acetate for the treatment of non-metastatic and locally advanced, high-risk, hormone-sensitive prostate cancer (OW20): Issue date: 07/11/2022

Vonicog alfa (Veyvondi®) for on-demand treatment of bleeding episodes in children with von Willebrand Disease (OW19): Issue date: 07/11/2022

Mepolizumab (Nucala®) for chronic eosinophilic pneumonia (OW15): Last review date: 17/05/2022

Sorafenib for acute myeloid leukaemia (AML) maintenance (OW18): Issue date; 14/04/2022

Rituximab for interstitial lung disease (OW13): Last review date: 29/12/2021

Adalimumab for paediatric intermediate, posterior and pan-uveitis (OW04): Last review date: 26/07/2021

Follow AWTTC: